Brief: Krystal Biotech Announces Pipeline Expansion Into Oncology And FDA Acceptance Of Ind Application
26/07/2023 21:29
July 26 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES PIPELINE EXPANSION INTO ONCOLOGY
AND
FDA ACCEPTANCE OF IND APPLICATION FOR LEAD ONCOLOGY CANDIDATE
KB707
* KRYSTAL BIOTECH INC - PLANNING TO FILE AMENDMENT TO KB707
IND IN
H2 2023 TO EVALUATE INHALED KB707 IN A CLINICAL TRIAL IN FIRST
HALF OF 2024
* KRYSTAL BIOTECH-FDA ACCEPTED CO'S IND TO EVALUATE
INTRATUMORAL
KB707 IN PATIENTS WITH SOLID TUMORS ACCESSIBLE BY TRANSCUTANEOUS
INJECTION
* KRYSTAL BIOTECH-EXPECTS TO INITIATE PHASE 1 STUDY TO
EVALUATE
INTRATUMORAL KB707 IN H2 2023
Further company coverage: KRYS.O
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion